NERVGEN PHARMA CORP. R&D Expense

by

Quick Answer

NERVGEN PHARMA CORP. reported r&d expense of C$13.91 million for fiscal year 2025 (IFRS, Form 20-F).

Reported under IFRS (SEC Form 20-F). Figures are shown in USD where the company provided them, otherwise in its reporting currency — each value exactly as filed with the SEC, not converted.

NERVGEN PHARMA CORP. R&D Expense — Annual History

Fiscal Year R&D Expense YoY Change
2025 C$13.91M -12.0%
2024 C$15.81M —
  • NERVGEN PHARMA CORP.’s r&d expense fell 12.0% year over year.
  • The most recent figure is from NERVGEN PHARMA CORP.’s fiscal year 2025 annual report (Form 20-F), filed March 31, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 19, 2026.

Last verified:

Leave a Comment